A Frenzy Of Lobbying On 21st Century Cures
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
Drug Costs
641-660 of 705 results
-
-
Long-Stalled FDA Reform Sits On Senate’s Lame-Duck Calendar
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.
-
California’s Drug Price Initiative: Will Voters ‘Send A Signal To Washington’?
Despite heavy opposition from the pharmaceutical industry and skepticism from policy experts, many voters see Proposition 61 as a way to protest the nation’s mounting drug prices.
-
Drug Prices, Not The Health Law, Top Voters’ Health Priorities For 2017
Majorities of Democrats, Republicans and independents support making sure high-cost drugs for chronic conditions are affordable.
By Julie Rovner -
West Virginia Grapples With High Drug Costs
Climbing drug prices are taking a toll on West Virginia's budget, some state legislators say. Expensive drugs fuel an increase in Medicaid spending, which leaves less money for schools and roads.
-
7 Insurers Alleged To Use Skimpy Drug Coverage To Discourage HIV Patients
The plans sought to discourage costly HIV patients by not including their drug needs in formularies or requiring high cost sharing, a Harvard Law School group says in a complaint filed with HHS.
-
Hospitals Say They’re Being Slammed By Drug Price Hikes
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
-
Tracking Who Makes Money On A Brand-Name Drug
KHN’s Julie Appleby joined forces with USA Today to create this chart, which details the various industry players and how they contribute to a prescription drug’s cost.
-
Young Boy’s Struggle To Survive Sparked Push For Drugs For Terminally Ill
Ten-year-old Josh Hardy died last month. His struggle to survive helped to spur laws to get unapproved drugs to the terminally ill.
By Liz Szabo -
The Orphan Drug Machine
A Golden Ticket That Fast-Tracks A Drug Through The FDA
A voucher awarded to companies that find treatments for rare childhood diseases can be sold to the highest bidder — and then used to speed up approvals for much more common drugs.
-
Specialty Drug Costs Soar 30% For California Pension Fund
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
By Chad Terhune -
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
By Julie Appleby and Mary Agnes Carey -
Veterans Courted In California’s Ballot Fight Over Curbing Drug Prices
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
-
FDA Approves First Drug To Treat Rare Form Of Muscular Dystrophy
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
By Liz Szabo -
Candidates Decry High Drug Prices, But They Have Few Options For Voters
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
By Julie Rovner -
Study: Health Spending Related To Opioid Treatment Rose More Than 1,300 Percent
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
-
Consumer Group Questions Role of Drug Costs In California Premium Hikes
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
By Chad Terhune -
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
-
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
-
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.